Anthracyclines improve survival in HER2-positive breast cancer patients

December 26, 2007

Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online December 25 in the Journal of the National Cancer Institute.

Randomized clinical trials have demonstrated that treating early breast cancer with anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens. However, the studies have demonstrated that anthracyclines may slightly increase the risk of heart damage and leukemia. Given these side effects, the greatest benefit of these regimens may be in women with breast tumors that overexpress HER2-a gene that is often amplified in tumors that respond to anthracyclines.

Alessandra Gennari, M.D., Ph.D., of the National Cancer Research Institute in Genoa, Italy, and colleagues compiled data from eight randomized controlled trials that compared anthracyclines and non-anthracyclines, and also reported HER2 status. Almost 30 percent of the patients' tumors overexpressed HER2.

Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.

"The absence-of any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations," the authors write.

In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.

"Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone," the editorialists write.

Journal of the National Cancer Institute

---

---

	Anthracycline-Induced Cardiomyopathy (Postgraduate Medicine) by JTE Multimedia Abstract: Anthracyclines are potent chemotherapeutic agents associated with 3 different forms of cardiomyopathy. Acute cardiomyopathy is seen within 3 months of drug exposure and may take the form of either a reversible myocarditis and pericarditis or an early-onset type and a late-onset type of chronic cardiomyopathy. Chronic anthracycline-induced cardiomyopathy is treated similarly to ischemic cardiomyopathies with beta-blockade and angiotensin-converting enzyme (ACE) inhibition. This review focuses on recent research regarding mechanisms of anthracycline-induced myocardial damage, the noninvasive imaging diagnosis of anthracycline-induced cardiomyopathy, and potential areas of future research regarding genetic screening and selecting individuals at increased risk, with consideration of...
	Anthracyclines: Webster's Timeline History, 1972 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Anthracyclines," including when used in literature (e.g. all authors that might have Anthracyclines in their name). As such, this book represents the largest compilation of timeline events associated with Anthracyclines when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	Anthracycline: Webster's Timeline History, 1974 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Anthracycline," including when used in literature (e.g. all authors that might have Anthracycline in their name). As such, this book represents the largest compilation of timeline events associated with Anthracycline when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...
	Anthracycline Chemistry and Biology I: Biological Occurence and Biosynthesis, Synthesis and Chemistry (Topics in Current Chemistry) by Karsten Krohn (Editor) Still valid and useful after up to a decade, this series presents critical reviews of the present position and future trends in modern chemical research. It is made up of short and concise reports on chemistry, each written by the world renowned experts.
	Anthracyclines: Current Status and New Developments by Stanley T. Crooke (Editor), S. Reich (Editor)
	Anthracycline Antibiotics by Hassan Saad El Khadem (Editor)
	Anthracycline Anticancer Agts (Bioactive molecules) by LOWN (Author)
	Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of Action (Acs Symposium Series) by Waldemar Priebe (Editor) Covers the synthesis of promising new analogues. Studies structure-activity relationships of anthracycline antibiotics. Investigates new approaches to improving properties for anthracyclines by using different drug-delivery and tumor-targeting systems. Covers the mechanisms of action of anthracyclines, their interactions with cellular targets, and related biological and clinical aspects.
	Anthracyclines: Current status and future developments by Masson Pub. USA (Publisher)
	Anthracycline Antibiotics in Cancer Therapy (Developments in Oncology 10) by Franco M.; Carter, Stephen K.; Young, C. W. Muggia (Author)